Brainstorm Cell Therapeutics Inc. Stock News

Northern Trust Corp decreased its holdings in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) by 83.4% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 49,761 shares of the biotechnology companys stock after selling 249,672 shares during the period. Northern Trust Corp owned 0.14% []

Charles Schwab Investment Management Inc. cut its holdings in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) by 85.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,287 shares of the biotechnology companys stock after selling 66,828 shares during the quarter. Charles Schwab Investment []

(RTTNews) - BrainStorm Cell Therapeutics Inc. (BCLI) reported new analyses from the phase 3 trial of NurOwn in amyotrophic lateral sclerosis. It showed that although the phase 3 trial did not reach statistical significance on the primary and secondary endpoints, pre-specified and post hoc analyses leveraging different methods of exploring the

NEW YORK, Nov. 29, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the presentation of new analyses from the Phase 3 trial of NurOwn at the 4th Annual ALS ONE Research

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) shares, rose in value on Friday, 11/26/21, with the stock price up by 9.04% to the previous days close as strong demand from buyers drove the stock to $3.74. Actively observing the price movement in the last trading, the stock closed the session at $3.43, falling within a range of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) Surged 9.04%, So What Now? Read More »

The Gene and Cell Therapies Targeting CNS Disorders Market report focus on the current trends of the market along with detailed analysis which provides data regarding this market rate, and it also predicts the future market growth rate. The Gene

Analysts forecast that Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) will announce ($0.23) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Brainstorm Cell Therapeutics earnings, with the lowest EPS estimate coming in at ($0.24) and the highest estimate coming in at ($0.21). Brainstorm Cell Therapeutics posted earnings []

Brainstorm Cell Therapeutics (NASDAQ:BCLI) issued its quarterly earnings data on Sunday. The biotechnology company reported ($0.15) earnings per share for the quarter, topping the Thomson Reuters consensus estimate of ($0.21) by $0.06, MarketWatch Earnings reports. During the same quarter in the prior year, the firm earned ($0.14) EPS. Shares of Brainstorm Cell Therapeutics stock opened []

Brainstorm Cell Therapeutics Inc. (BCLI) CEO Chaim Lebovits on Q3 2021 Results - Earnings Call Transcript

Analysts forecast that Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) will post earnings of ($0.21) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Brainstorm Cell Therapeutics’ earnings. The highest EPS estimate is ($0.18) and the lowest is ($0.24). Brainstorm Cell Therapeutics reported earnings per share of ($0.14) during the same quarter […]

Brainstorm Cell Therapeutics (NASDAQ:BCLI) is scheduled to post its quarterly earnings results before the market opens on Monday, November 15th. Analysts expect Brainstorm Cell Therapeutics to post earnings of ($0.21) per share for the quarter. Shares of BCLI traded down $0.01 during mid-day trading on Friday, hitting $2.97. 130,394 shares of the company’s stock were […]

NEW YORK, Oct. 18, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation today of

NEW YORK, Oct. 14, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, will present findings from a multic